OTCWagon Issues Update for Immunoprecise Antibodies Ltd. (IPA)

VICTORIA, British Columbia - May 14, 2020 - PRLog -- Immunoprecise receives $75,000 (U.S.) in gov't funding

The State of North Dakota has awarded Immunoprecise Antibodies Ltd. a bioscience innovation grant totalling $75,000 (U.S.) for the enhancement of a novel platform for rapidly developing treatments for COVID-19 and other emerging pathogens.

"Advances in bioscience have already transformed many sectors, including agriculture and medicine," said North Dakota Agriculture Commissioner Doug Goehring. "These grants will help North Dakota stay on the forefront of bioscience innovation."

This grant was the first application of many to be submitted by Immunoprecise Antibodies over the next several months.

"Immunoprecise is in the process of applying for both state and federal grants to support the development of a treatment for COVID-19 using our PolyTope mAb therapy," stated Jennifer Bath, Immunoprecise's president and chief executive officer. "We turned first to the State of North Dakota, given their strong history of support for biotechnology and innovation. It is with gratitude we accept the ND bioscience innovation grant, and we are confident we can leverage this funding, along with our research advances, to continue to build on our current successes."

About Immunoprecise Antibodies Ltd.

Immunoprecise is a full-service, therapeutic antibody discovery contract research organization offering species-agnostic, multiformat, characterized and engineered, human monoclonal antibodies, on an abbreviated time frame, for its pharmaceutical clients.